Drug Trial Radar · NCT02706873
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate
Last checked: Nov 19, 2026Latest source record: Jul 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,002
Actual
Start
Feb 23, 2016
Primary completion
Mar 15, 2018
Study completion Nov 10, 2022
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 11, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of Period 1 were the following: * To compare the safety and efficacy of upadacitinib 7.5 mg once daily (QD) monotherapy (for participants in Japan only), 15 mg QD monotherapy, and 30 mg QD monotherapy versus weekly methotrexate monotherapy for the treatment of signs and symptoms of RA in methotrexate-naïve adults with moderately to severely active RA; * To compare the efficacy of upadacitinib 15 mg QD monotherapy and upadacitinib 30 mg QD monotherapy versus weekly methotrexate monotherapy for prevention of structural progression in methotrexate-naïve adults with moderately to severely active RA. The objective of Period 2 is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 7.5 mg QD (for participants in Japan only), 15 mg QD, and 30 mg QD in adults with RA who have completed Period 1.
Conditions
- Rheumatoid Arthritis
Interventions
Placebo to UpadacitinibDrug
Tablet; Oral
MethotrexateDrug
Capsule or Tablet; Oral
Placebo to MethotrexateDrug
Capsule or Tablet; Oral
UpadacitinibDrug
Tablet; Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 - Global AnalysisTime frame: Baseline and Week 12
- Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 24 - Global AnalysisTime frame: Week 24
- Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 - Global AnalysisTime frame: Baseline and Week 12
- Change From Baseline in Modified Total Sharp Score (mTSS) at Week 24 - Global AnalysisTime frame: Baseline to Week 24
Locations
290 sites in 45 countries. Site status is shown where the registry gives one.
TriWest Research Associates- La Mesa /ID# 143738
La Mesa, California
Desert Medical Advances /ID# 143730
Palm Desert, California
International Medical Research - Daytona /ID# 143748
Daytona Beach, Florida
FL Med Ctr and Research, Inc. /ID# 143724
Miami, Florida
Millennium Research /ID# 143736
Ormond Beach, Florida
Arthritis Research of Florida /ID# 143743
Palm Harbor, Florida
Sarasota Arthritis Center /ID# 145978
Sarasota, Florida
FL Med Clinic, PA /ID# 143744
Zephyrhills, Florida
Deerbrook Medical Associates /ID# 143728
Vernon Hills, Illinois
Four Rivers Clinical Research /ID# 143741
Paducah, Kentucky
Ocean Rheumatology, PA /ID# 143737
Toms River, New Jersey
Arthritis Rheumatic Back Disorder /ID# 143733
Voorhees Township, New Jersey
Trinity Health Med Arts Clinic /ID# 143727
Minot, North Dakota
STAT Research, Inc. /ID# 143750
Vandalia, Ohio
Healthcare Research Consultant /ID# 143747
Tulsa, Oklahoma
Advanced Rheumatology & Arthri /ID# 147947
Wexford, Pennsylvania
Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 145653
Summerville, South Carolina
West Tennessee Research Inst /ID# 143723
Jackson, Tennessee
Dr. Ramesh Gupta /ID# 143732
Memphis, Tennessee
Diagnostic Group Integrated He /ID# 152921
Beaumont, Texas
Adriana Pop-Moody MD Clinic PA /ID# 147626
Corpus Christi, Texas
Doctor's Hosp at Renaissance /ID# 156407
Edinburg, Texas
MedResearch Inc. /ID# 156409
El Paso, Texas
Rheumatic Disease Clin Res Ctr /ID# 151103
Houston, Texas
Accurate Clinical Research /ID# 143749
Houston, Texas
SW Rheumatology Res. LLC /ID# 143745
Mesquite, Texas
Sun Research Institute /ID# 159546
San Antonio, Texas
Accurate Clinical Management /ID# 159543
San Antonio, Texas
NextGen Clinical Trials LLP /ID# 150930
San Antonio, Texas
Arthritis Clinic of Central TX /ID# 159541
San Marcos, Texas
Arthritis & Osteoporosis Clinic /ID# 159542
Waco, Texas
Arthritis Clinic of N. VA, P.C /ID# 143734
Arlington, Virginia
Org Medica de Investigacion /ID# 143142
Buenos Aires, Argentina
Consultora Integral de Salud S /ID# 143144
Córdoba, Argentina
Centro Integral de Reumatologi /ID# 143143
San Miguel de Tucumán, Argentina
Centro Medico Privado/Reuma /ID# 143140
San Miguel de Tucumán, Argentina
Aprillus Asistencia e Investig /ID# 149179
Capital Federal, Buenos Aires, Argentina
Iari /Id# 148595
San Isidro, Buenos Aires, Argentina
Instituto CAICI /ID# 143141
Rosario, Santa Fe Province, Argentina
Royal Prince Alfred Hospital /ID# 143149
Camperdown, New South Wales, Australia
Showing 40 of 290 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.